In clinical studies of IMV-001, Living cells are harvested from the patient, and immediately treated with IMV-001, an IGF-1R antisense oligodeoxynucleotide that is designed to induce a stressed state, pushing the cells toward a regulated cell death. In addition, excess IMV-001 is added to be released as an adjuvant from the chambers at the implantation site. Treated samples are then encased in biodiffusion chambers with a sub-cellular exclusion limit that traps the tumor cells inside. These biodiffusion chambers are then irradiated and implanted the day after surgery in the patient’s abdomen. They remain implanted for 48 hours where they serve as a controlled depot release of antigens. This represents the IGV-001 investigational drug product.

Here’s how we do it:

Step 1:  Patient Cell Harvest, Treatment, and Implant

Step 2:  Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation

Step 3:  Long-term Adaptive Immune Activation and Response